Print this page
-
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery.
Protocol: 072201Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Pancreas -
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen.
Protocol: 072214Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Other Digestive Organ -
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2
Expression
Protocol: 072305Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Pancreas -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon
- 1
- 2